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Purpose: To quantify the association between dark adaptation parameters and other
clinical measures of visual function among people with and without early and interme-
diate age-related macular degeneration (AMD).
Methods: In this cross-sectional study, participants underwent multimodal imaging
and visual function testing, including best-corrected visual acuity (BCVA), low-
luminance visual acuity (LLVA), low-luminance deficit (LLD = BCVA – LLVA) and the
10-item Night Vision Questionnaire (NVQ-10). Dynamic and static dark-adapted
chromatic perimetry (DACP) was performed. Sensitivity difference was defined as the
difference in sensitivity between the 505-nm and 625-nm stimuli. Rod intercept time
(RIT) was estimated as the time required to reach a threshold of−3 log candelas/meter2
with the 505-nm stimulus following bleaching. The magnitude of association between
theDACPparameters andother clinical testswas estimated viamixed-effects regression.
Results: A total of 51 participants (aged 51–88 years, 65% female, 39% with AMD)
were included. RIT was found to be negatively associated with BCVA (P < 0.001), LLVA
(P= 0.005), andNVQ-10 score (P= 0.028) but not LLD (P= 0.763). Therewas no evidence
of an association between sensitivity difference and any of the clinical measures
(P≥ 0.081).
Conclusions: Reduced rod function, as determined by RIT, was associated with lower
NVQ-10 scores (designed to interrogate rod-mediated function) and with worse BCVA
and LLVA (measures of cone function).
Translational Relevance: Decreasing rod function maybe indicative of more gener-
alized photoreceptor dysfunction involving cones. Further development of question-
naires to target function in scotopic conditions may provide an easier to administer test
without the need to perform perimetric tests of rod function.
Introduction
Reductions in rod-mediated visual function have
been well documented as an early functional deficit
in age-related macular degeneration (AMD), present
evenwhen best-corrected visual acuity (BCVA) remains
unaffected.1–6 Indices of rod function have therefore
been suggested as potential early biomarkers of disease
severity in AMD and may potentially be used in clini-
cal trials to investigate the efficacy of new interven-
tions at early stages of disease in the absence of
anatomical signs of progression to late-stage AMD.7–9
However, the current psychophysical measurement of
rod function is time-consuming and logistically difficult
among elderly patients and in clinical settings.10
Other more simple clinical tests of visual function
have also been used to monitor functional changes
in the early stages of AMD.7,11 Low-luminance
visual acuity (LLVA) and low-luminance deficit (LLD)
have shown promise as potential functional biomark-
ers in clinical AMD trials.7,11 Several studies have
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documented poor performance of visual tasks in low-
luminance settings despite good visual acuity in the
early stages of AMD.7,11–14 In addition, questionnaires
that aim to interrogate visual function in dim or dark
conditions have also been derived in an attempt to
capture the difficulty experienced in the dark.12,15–18
However, in the early stages of AMD, it remains
uncertain how well the changes in rod function, as
assessed by formal perimetric testing, correlate with
these other tests and low-luminance questionnaires,
which also aim to capture the difficulties experienced
in the early stages of disease before BCVA is affected.
Therefore, the purpose of this study was to deter-
mine the association between rod-mediated sensitiv-
ity measured via dark-adapted chromatic perimetry
(DACP) and each of BCVA, LLVA, LLD and the
10-item Night Vision Questionnaire (NVQ-10).
Methods
This was a cross-sectional observational study that
was approved by the Human Research and Ethics
Committee of the Royal Victorian Eye and Ear Hospi-
tal. Written informed consent conforming to the tenets
of the Declaration of Helsinki was acquired from all
participants prior to commencing the study.
Participants
Participants were recruited from existing prospec-
tive natural history research cohorts in the Macular
Research Unit at the Centre for Eye Research
Australia, Melbourne, Australia, between 2015 and
2017. Control participants were recruited from
spouses, friends, and relatives of the AMD partici-
pants and from among staff.
Eligibility criteria for this analysis included age
≥50 years with BCVA of ≥60 letters (equivalent to
6/19 or 20/63). When both eyes were eligible to be
included, the eye with the best BCVA was chosen as
the study eye.
Participants with evidence of current or past
neovascular AMD or geographic atrophy (as defined
below) in either eye were excluded, as were partic-
ipants with ungradable retinal images. Participants
with unilateral reticular pseudodrusen (RPD)were also
excluded, as RPD is known to affect dark adaptation
and may be a confounding factor when investigating
the relationship between uniocular rod function and
NVQ-10 score (which relates to binocular vision).19
Exclusion criteria for both groups included people
with grade 2 cataract or worse (World Health Organi-
zation [WHO] grading system), diabetic retinopathy,
glaucoma, neck or spinal problems preventing comple-
tion of DACP, or medications that might affect retinal
function such as hydroxychloroquine.20 In addition,
participants with medical conditions that could affect
dark adaptation (such as liver disease and renal disease)
were excluded.21,22
Visual Acuity
BCVA was measured at 4 meters using a modified
count-letters version of the Early Treatment of
Diabetic Retinopathy Study protocol.23 LLVA was
measured under the same condition but with the
addition of a 2.0 neutral density filter in front of the
study eye. LLD was calculated by subtracting LLVA
fromBCVA.24 All visual acuitymeasures were recorded
with best refractive correction.
NVQ-10
The NVQ-10 possesses two distinct subscales to
assess self-reported visual function in low luminance.17
The first subscale relates to car travel and has five
response options ranging from no difficulty at all
to stopped doing because of my eyesight as seen in
Supplementary Table S1. Additional response options,
stopped doing for reasons other than my eyesight and
not currently driving, were treated as missing for the
purposes of this analysis. The second subscale relates to
how bothered participants are by their vision and has
four response options ranging from not at all to very.
DACP
Pupils were dilated to a minimum of 6 mm
with 0.5% tropicamide (Mydriacyl; Alcon Laborato-
ries, NSW, Australia). Sphero-cylindrical lens correc-
tion was inserted into a lens holder with the refrac-
tive correction set up for a viewing distance of 30
cm. Fixation was monitored via an infrared-activated
camera throughout testing. All participants were given
the same instructions prior to testing.
The Medmont DACP (Medmont International Pty
Ltd, Nunawading, Australia) has two color stimuli, one
at 505 nm (cyan, dynamic range of 0–75 dB) and the
other at 625 nm (red, dynamic range of 0–50 dB).25
Stimuli of 1.73° in diameter (Goldmann size V) were
presented for durations of 200 ms. Thresholds were
determined using a 4-2 staircase threshold strategy.25
Dynamic threshold testing was conducted following
20% bleaching of the rod photopigment from a single
flash of approximately 2.45× 106 scotopic candelas per
meter squared (cd/m2) in intensity from a customized
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Ganzfeld stimulator (Mecablitz 45 CL-4; Metz-Werke
GmbH&Co., Zirndorf, Germany).26 Over 30 minutes,
the sensitivity to the 505-nm stimulus was measured at
14 test locations 4°, 5.7°, 8°, and 12° from the fovea.
Static threshold testing was then conducted using
the 625-nm (red) stimuli, which was undertaken follow-
ing a short break to avoid fatigue. Twenty-four test
loci in total were located at 4°, 5.7°, 8°, 12°, 17°, and
24° from the fovea.
All testing was performed monocularly with the
fellow eye occluded.
Retinal Imaging and Classification
All participants underwent multimodal imaging
(near-infrared reflectance, short-wavelength fundus
autofluorescence, optical coherence tomography
[Spectralis HRAþOCT; Heidelberg Engineering,
Heidelberg, Germany], and color fundus photography
[Canon CR6-45NM; Canon, Saitama, Japan]), which
was performed following functional assessment to
prevent retinal bleaching. Grading was performed
by trained graders who were masked to participant
characteristics.
AMD was classified according to the Beckman
classification system.27 Control participants had no
apparent aging changes (no drusen and no AMD
pigmentary abnormalities) or drupelets (small drusen
≤63 μm) only.27 In the absence of geographic atrophy
(defined within a radius of 3000 mm from the fovea,
as any area >175 mm in diameter of partial or
complete retinal pigment epithelium hypopigmenta-
tion with visible underlying large choroidal vessels that
was either roughly round or oval and showed sharp
margins on color fundus photography) or choroidal
neovascularization detected on any imaging modal-
ity, participants with drusen sized 63 to <125 μm
without pigmentary abnormalities were considered to
have early AMD, and those with drusen >125 μm or
drusen 63 to <125 μm with pigmentary abnormali-
ties were considered to have intermediate AMD. RPD
were defined as clear round or cone-shaped subretinal
deposits between external limiting membrane or outer
plexiform layers and retinal pigment epithelium and
determined using all imaging modalities.28,29
Crystalline Lens Grading
Lens status was assessed through dilated pupils
using slit-lamp microscopy and graded according to
the WHO classification scheme after tests of visual
function had been completed.20
Data Analysis
It has previously been shown that AMD status has
a greater impact on rod function for loci in the central
visual field than those peripherally.19,30 Therefore, only
DACP data from the central 8° (12 loci) were analyzed
(as specified a priori).
The sensitivity difference between the 505-nm and
625-nm stimuli (cyan—red sensitivity difference) was
derived at each locus to enable psychophysical assess-
ment of rod-mediated function based on the two-color
perimetry principle.19,25 In dark-adapted healthy eyes,
the sensitivity to the 505-nm stimulus is expected to
be greater than that of the 625-nm stimulus. Rod cells
absorb 505-nm stimuli to a greater extent than cone
cells but are insensitive to the 625-nm stimulus, which is
detected by cones.6 Therefore, the sensitivity difference
becomes smaller as rod function declines in relation to
cone function.
Rod intercept time (RIT) was defined as the time
required following bleaching for sensitivity to recover
to −3.0 log cd/m2 stimulus intensity for each test
locus.30 The relationship between luminance and time
has previously been modeled as a series of exponen-
tial decay functions.31,32 For this analysis, we used
the formula previously presented by our group and
derived the parameters of this model using nonlinear
least squares estimation.26,33 RIT was then determined
algebraically using these estimation parameters. The
statistical computing code used to estimate the RIT is
presented in the Supplementary Material. RIT could
not be estimated for test loci with sensitivity better
than −3 log cd/m2 prior to the first response to stimuli
(indicating unreliable responses or incomplete bleach-
ing) or if sensitivity did not recover to better than −3
log cd/m2 within 30 minutes of testing.
DACP values from each ring were compared
betweenAMDparticipants and controls using Somers’
D statistic, accounting for within-participant correla-
tion.
Estimates of the latent trait of visual function in low
luminance were derived from NVQ-10 responses. The
first two response categories for questionnaire items 1
to 4 were collapsed due to low response rates for these
categories (see Supplementary Table S1). A partial-
credit model was then used to estimate NVQ-10 scores
due to a violation of the rating scale model assumption
of step invariance.34
The association between RIT and NVQ-10 score,
BCVA, LLVA, and LLD was found to be approx-
imately linear after log-transformation of RIT
(see Fig. 1). Therefore, the relationship between the
natural logarithm of DACP parameters and each of
the other tests was investigated via mixed-effects linear
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Figure 1. Scatterplots of the relationship between the average of the natural log of RIT and each of BCVA, LLVA, LLD, and NVQ-10 score
(n= 51). ρ = Pearson’s correlation coefficient for average log-RIT for each participant and each of BCVA, LLVA, LLD, and NVQ-10.
regression, adjusting for lens status and age (specified
as potential predictors of rod function a priori) and
accounting for within-person and within-ring correla-
tion. The identity variance-covariance structure was
chosen for the random effects, and the model was fit
via restricted maximum likelihood estimation. This
relationship was graphically inspected using scatter-
plots of the mean log-transformed DAPC parameters
for each participant against each of the other test
parameters that were presented with Pearson’s corre-
lation coefficients.
A complete case analysis was performed; that
is, only participants with data on RIT, sensitivity
difference, NVQ-10, and visual acuity variables were
included. Statistical analyses were performed using
Stata/SE 16.0 (StataCorp LLC, College Station, TX,
USA).
Results
A total of 103 participants were screened for inclu-
sion. Data from 51 participants (50%) remained after
exclusions (see Supplementary Figure S1 for partic-
ipant flowchart). A summary of demographic and
clinical data for included participants is presented
in Table 1. Participants ranged from 51 to 88 years of
age, and the majority were female (65%). Early AMD
was detected in 5 participants (10%), and 15 (29%)
had intermediate AMD. There were 31 age-matched
control participants.
DACP
All participants were considered reliable, with false-
positive rates of less than 10%. A total of 582 loci
from 51 participants were included in the analyses. RIT
was estimated for all 12 loci among 42 of 51 partici-
pants (82%). Of the remaining nine participants with at
least one locus for which RIT could not be estimated,
six AMD participants (with bilateral RPD) had RIT
estimated to be greater than 30 minutes and three
control participants with loci that had reached adapta-
tion prior to ascertainment of threshold.
Summary statistics for each parameter of interest
are presented in Table 2 according to distance from
fixation andAMDstatus. In general, there was stronger
evidence for a difference between AMD and control
participants when assessing loci at 4° and 5.657° from
fixation (compared to loci at 8°) and when assessing
RIT (compared to otherDACPparameters). Therewas
a weak correlation between RIT and sensitivity differ-
ence values (Spearman’s correlation −0.16; 95% confi-
dence interval, −0.24 to −0.08).
NVQ-10
Ceiling effects were observed forNVQ-10 responses,
indicating that many participants reported no visual
impairment in mesopic conditions (see Supplementary
Table S1 for tabulation of responses to each item). Ten
percent of participants did not drive a car for reasons
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Table 1. Participant Demographic and Clinical Characteristics
Characteristic AMD (n= 20) Control (n= 31) Total (N= 51)
Age, mean (SD), y 69.8 (7.5) 66.1 (9.6) 67.6 (8.9)
Sex, n (%)
Male 5 (25) 13 (42) 18 (35)
Female 15 (75) 18 (58) 33 (65)
Lens status, n (%)a
Clear 13 (65) 19 (61) 32 (63)
Intraocular lens 1 (5) 1 (3) 2 (4)
Cataract 6 (30) 11 (35) 17 (33)
NVQ-10 score (logits), median (IQR) 0.1 (−0.9, 0.7) 1.0 (0.1, 1.0) 0.4 (−0.4, 1.0)
BCVA (letters), mean (SD)a,b 84.4 (5.0) 89.6 (4.7) 87.6 (5.4)
LLVA (letters), mean (SD)a,b 73.0 (7.5) 78.5 (7.2) 76.4 (7.7)
LLD (letters), mean (SD)a,b 11.4 (4.1) 11.1 (3.5) 11.3 (3.7)
IQR, interquartile range.
aValues from a single eye (the study eye) per participant.
bMissing values for one control participant.
other than poor eyesight; items 1 to 3 were therefore
not applicable for these participants.
There was a weak negative association between
NVQ-10 score and RIT, as seen in Table 3 (age-
and lens-adjusted estimates) and Figure 1 (unadjusted
correlation). However, there was no evidence of an
association between NVQ-10 and sensitivity difference
(Fig. 2).
Table 2. Dark-Adapted Chromatic Perimetry Values by Distance from Fixation and Age-Related Macular Degen-
eration Status
Median (Interquartile Range)
Characteristic Total (N= 51) AMD (n= 20) Control (n= 31) P Valuea
Cyan threshold (505 nm), dB
All pointsb 52.0 (48.0, 56.0) 50.0 (48.0, 52.0) 52.0 (48.0, 56.0) 0.005
4° 48.0 (46.0, 52.0) 48.0 (44.0, 48.0) 49.0 (48.0, 52.0) 0.002
5.657° 52.0 (48.0, 56.0) 50.0 (48.0, 52.0) 54.0 (50.0, 56.0) <0.001
8° 54.0 (50.0, 56.0) 52.0 (50.0, 56.0) 54.0 (50.0, 56.0) 0.158
Red threshold (625 nm), dB
All pointsb 30.0 (28.0, 34.0) 30.0 (28.0, 32.0) 32.0 (30.0, 34.0) 0.003
4° 30.0 (26.0, 30.0) 28.0 (26.0, 30.0) 30.0 (28.0, 32.0) 0.003
5.657° 30.0 (28.0, 34.0) 30.0 (28.0, 30.0) 32.0 (30.0, 34.0) 0.002
8° 32.0 (30.0, 34.0) 30.0 (30.0, 32.0) 34.0 (30.0, 34.0) 0.005
Sensitivity difference, dB
All pointsb 20.0 (18.0, 24.0) 20.0 (18.0, 22.0) 22.0 (18.0, 24.0) 0.204
4° 20.0 (18.0, 22.0) 20.0 (18.0, 22.0) 20.0 (18.0, 22.0) 0.381
5.657° 22.0 (20.0, 24.0) 20.0 (18.0, 22.0) 22.0 (20.0, 24.0) 0.019
8° 22.0 (20.0, 24.0) 22.0 (20.0, 24.0) 22.0 (18.0, 24.0) 0.771
Rod intercept time, min
All points* 7.2 (5.9, 9.8) 9.9 (7.6, 12.8) 6.5 (5.4, 7.9) <0.001
4° 7.0 (5.7, 9.8) 10.0 (7.8, 14.0) 6.3 (5.3, 7.8) <0.001
5.657° 7.2 (5.8, 9.9) 9.9 (7.7, 12.7) 6.3 (5.5, 7.6) <0.001
8° 7.4 (6.0, 9.8) 9.5 (7.5, 12.3) 6.7 (5.5, 8.0) <0.001
n= number of participants, with multiple test points within each ring for each participant (528 test loci total).
aPvalues comparingAMDtocontrol participants estimatedusingSomers’D statistic accounting forwithin-participant corre-
lation.
bThreshold values and rod intercept time values taken from all visual field loci within 8° from fixation for a single eye per
participant.
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Table 3. Association Between Dark-Adapted Chromatic Perimetry Values and Other Clinical Tests (N= 51 Partici-
pants)
Rod Intercept Time Sensitivity Difference
Characteristic % Change 95% CI P Valuea % Change 95% CI P Valuea
BCVA (per letter increase) −4.2 −6.2 to −2.2 <0.001 0.5 −0.1 to 1.1 0.081
LLVA (per letter increase) −2.2 −3.7 to −0.7 0.005 0.2 −0.2 to 0.6 0.334
LLD (per letter increase) 0.5 −2.7 to 3.9 0.763 0.2 −0.6 to 1.0 0.650
NVQ-10 score (per logit increase) −14.7 −25.9 to −1.7 0.028 1.5 −2.2 to 5.4 0.422
CI, confidence interval.
aEstimated usingmixed-effects linear regression with log-transformed values of rod intercept time or sensitivity difference,
adjusted for age and lens status, with random intercepts for participant and distance from fixation.
Figure 2. Scatterplots of the relationship between average of the natural log of sensitivity difference and each of BCVA, LLVA, LLD, and
NVQ-10 score (n = 51). ρ = Pearson’s correlation coefficient for average log-sensitivity difference for each participant and each of BCVA,
LLVA, LLD, and NVQ-10.
Measures of Visual Acuity
BCVA ranged from 74 (6/9.5 or 20/32) to
100 letters (6/6 or 20/20). RIT was estimated to
decrease with increases in BCVA and LLVA (adjusted
difference−4.2% and−2.2% per letter increase, respec-
tively; see Table 3 and Fig. 1). However, no association
could be found between LLD and RIT. No evidence
of an association was detected between sensitivity
difference and any of the visual acuity-based tests
(P ≥ 0.081).
Discussion
The primary aim of this study was to investigate
the association between rod function (as measured via
DACP) and other clinical measures of visual function.
We found a negative correlation between RIT and
both BCVA and LLVA as well as a weak correla-
tion between RIT and self-reported low-luminance
vision.
A strong association was observed between RIT, a
test of rod-mediated function, and BCVA, a test of
cone function. This implies that in the early stages
of AMD, even though we find BCVA to be fairly
normal, there are indications of a subtle decline
of visual acuity along with the better-recognized
decline in rod function. The association between the
formal testing of rod function by RIT and of self-
reported visual function in dim conditions by NVQ-
10 was not as strong as that seen between RIT and
BCVA.
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Comparison to Previous Literature
Flamendorf and coauthors35 also reported amoder-
ate negative correlation between RIT (assessed at a
single locus) and BCVA. A slightly stronger associ-
ation between RIT (assessed at a single locus) and
self-reported low-luminance vision was found among
people with intermediate AMD and healthy controls
by Yazdanie and coauthors.36 In that study, self-
reported outcomes were assessed using the 32-item
Low Luminance Questionnaire (LLQ-32).12 With
more than three times the number of items than the
NVQ-10, the LLQ-32 can better discriminate between
levels of functional vision than the NVQ-10.
Our group has previously reported on the relation-
ship between NVQ-10 scores and clinical measures of
visual function among people with bilateral intermedi-
ate AMD.14 In that study, self-reported visual function
was more highly correlated with LLD than with LLVA.
In the present study, which included participants with
early AMD and healthy controls as well as participants
with intermediate AMD, we found RIT to be more
concordant with LLVA than LLD. This variation may
be due to different populations or may simply repre-
sent random variation. However, LLVA and LLD are
known to be correlated.
Strengths and Limitations
Dark adaptation was only measured over a period
of 30minutes, which is less than some other studies.35,36
Therefore, RIT could not be estimated for all loci of
all participants. However, the number of participants
with RIT from any locus estimated to be greater than
30 minutes was small, and all participants were able to
be included in the analyses due to the statistical model-
ing approach (which does not require participants to
have data at every visual field locus).
Reduction in cyan-red sensitivity represents decline
in rod function relative to cone function. However,
the sensitivity difference will underestimate the magni-
tude of rod function dysfunction if cone cell function
is also abnormal.6 For this reason, participants with
pathology other than AMD were excluded from this
study.
The NVQ-10 was not designed using modern
psychometric approaches,17 and newer instruments
designed to capture vision-related quality of life in low-
luminance settings may show greater a correlation with
rod function. This brief low-luminance questionnaire
was chosen due to the extensive nature of the functional
testing and multimodal imaging protocol for the study.
However, exploration of the utility of the NVQ-10
within the context of intermediate AMD recently
conducted by our group suggested that its brevity may
contribute to suboptimal performance.37 In addition,
NVQ-10 scores reflect visual function in binocular
conditions, whereas the other clinical measures repre-
sent uniocular visual function. Therefore, the non–
study eye may have attenuated estimates of associa-
tion between NVQ-10 and visual function. Question-
naire responses are subject to recall bias, and differ-
ences in lived experience may lead to divergent levels
of self-reported functional vision for individuals with
the same functional capabilities. In addition, ceiling
effects were apparent among this cohort of partici-
pants with relatively good visual function. It is possi-
ble that a stronger relationship between NVQ-10 and
DACP parameters may be detectable among people
with greater levels of visual impairment. Notwith-
standing, we found a weak-to-moderate correlation
between NVQ-10 scores and RIT.
The current study has a relatively small sample;
however, despite this we did observe significant associ-
ations between RIT and other clinical measures of
visual function. Additional participants with a range
of phenotypes typical of early and intermediate AMD
would have allowed a more detailed investigation
into the modifying effect of disease status on the
relationship between DACP and the other parameters.
Furthermore, a larger sample size may have revealed
evidence of associations between the cyan-red sensi-
tivity difference and the visual acuity–based tests that
were reported as inconclusive in this study.
Strengths of our study included the systematic and
consistent testingmethods and data collection, detailed
retinal grading, disease classification based on multi-
modal imaging, and the inclusion of control partic-
ipants. In addition, sensitivity was tested at multiple
retinal loci, and modern statistical approaches were
employed to provide valid estimates of association.
Biological Mechanisms
The reduction of retinal sensitivity in the central
visual field of people with AMD is consistent with the
known pattern of rod cell loss, which is greatest in the
parafoveal region.38,39 BCVA, LLVA, and NVQ-10 are
measures of cone function but also require parafoveal
involvement. We hypothesize that a subtle decline of
visual acuity, in the magnitude of letters rather than
lines, may occur early in the AMD process and that the
differences in function detected in this study are indica-
tive of dysfunction in both rod and cone cells.
Future Research
Our group has previously reported on changes in
rod sensitivity over a 12-month period among people
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with intermediate AMD and controls.30 However,
during that study period, the clinical AMD status of
participants did not change (i.e., none of the partici-
pants progressed from control to AMD or from inter-
mediate to late AMD). Prolonged follow-up of a larger
sample is required to assess the covariance between
measures of visual function and anatomical markers of
disease progression.
Currently available low-luminance questionnaires
often display ceiling effects in the absence of late
AMD.12,36 A more robust instrument for captur-
ing self-reported low-luminance visual function would
allow the relationship between retinal sensitivity and
functional vision to be investigated in more detail.40 In
addition, assessing both eyes of each participant via
DACP will allow a more valid comparison with vision-
related quality-of-life instruments that relate to binoc-
ular function.
Conclusions
In this cross-sectional study, we found that RIT was
associated with BCVA, LLVA, and NVQ-10 score. A
decrease in rod function in the early stages of AMD
may be indicative of more generalized photorecep-
tor dysfunction, involving cones as well rods. Further
work on questionnaires that specifically target visual
function in dim and dark conditions may provide an
easy to administer test that provides useful data on rod
function without the need to perform more difficult
perimetric tests of rod function.
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